Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.

US #biotech #VorBio has turned to China's #RemeGen to revitalise its pipeline, paying $125 million upfront for rights to a drug already approved in its home market for multiple #autoimmunediseases.

pharmaphorum.com/news/vor-bio...